Paradigm Health today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in the United States evaluating an FDA-approved therapy in patients ...
Today, Paradigm Health announced the launch of a landmark research collaboration with the U.S. Food & Drug Administration (FDA) focused on advancing a new model to accelerate clinical trial execution ...
NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass., July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NRSN) (NASDAQ: NRSN) ("NeuroSense"), a late-clinical ...
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured US Medicare reimbursement eligibility for eligible procedures in its global pivotal PARADIGM Trial, a prospective, randomised controlled ...
Bristol Myers Squibb is putting Paradigm’s plans to rebuild the clinical trial system to the test, teaming up with the startup to design studies that can activate community health provider ...
CAMBRIDGE, Mass., July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results